Previous 10 | Next 10 |
home / stock / huma / huma articles
The CNN Money Fear and Greed index showed a slight increase in the overall market sentiment on Thursday. U.S. stocks closed higher on Thursday...
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-tha...
DURHAM, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected thir...
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 100 points on Friday. Shares of Hewlett Packard Enterprise...
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univers...
Humacyte, Inc. (NASDAQ:HUMA) shares are trading higher on Friday. The company announced that the U.S. FDA has accepted and granted Priori...
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. Shares of The Boeing Company (NYSE: BA) rose duri...
News, Short Squeeze, Breakout and More Instantly...
Humacyte Inc. Company Name:
HUMA Stock Symbol:
NASDAQ Market:
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human pri...
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinica...
2024-05-30 12:06:59 ET Humacyte (NASDAQ: HUMA) stock price has surged hard since I wrote about it in April. It soared to a high of $9.35 on Thursday and is now trading at its highest point since December 2021. It has risen for seven straight weeks and is up by almost 370% from its l...